Loading company…
Montpellier biotech developing N-glycosylation inhibitors as anti-cancer therapies that aim to restore immune response against tumors.
Phost'in Therapeutics was founded in 2014 in Montpellier, France, and focuses on Glyco-Immuno-Oncology. It develops anti-cancer new chemical entities, including first-generation N-glycosylation inhibitors intended to help the immune system act against aggressive solid tumors, with products aimed at oncology healthcare providers and research institutions. The company has completed six deals; its most recent, on November 21, 2022, raised EUR 4.30 mn led by Remiges BioPharma Fund, with participation from ANRI. Clarion Ludovic, David Virieux and Karine Chorro founded the company, and Karine Chorro serves as CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in